Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005888 · ClinicalTrials.gov registry record · Phase 3
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT01005888 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 26 participants.
The verdict
NCT01005888, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.
Interventions
- DRUG Placebo (saline)
- BIOLOGICAL C1 esterase inhibitor [human] (C1INH-nf)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-03-14 |
| Est. Completion | 2007-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005888
The ClinicalTrials.gov registry entry for NCT01005888 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (saline) is the first listed.
NCT01005888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005888 about?
NCT01005888 is a clinical study titled "C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks". The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.
What is the current status of trial NCT01005888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2005-03-14. Estimated completion is 2007-08-22.
What interventions are being tested in trial NCT01005888?
The interventions under investigation include: Placebo (saline) (DRUG), C1 esterase inhibitor [human] (C1INH-nf) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01005888?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.